Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Abdominal examination

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    245 result(s) found for: Abdominal examination. Displaying page 1 of 13.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-005166-31 Sponsor Protocol Number: 3074K4-3340-WW Start Date*: 2009-09-15
    Sponsor Name:Wyeth Pharmaceuticals Inc., acting through its division Wyeth Research, a Pfizer Company
    Full Title: A Phase 3, Multicenter, Randomized, and Double-blind Study to Evaluate the Safety of Tigecycline versus a Ceftriaxone Regimen in the Treatment of Complicated Intra-abdominal Infections and Communit...
    Medical condition: Complicated Intra-Abdominal Infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056570 Intra-abdominal infection LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) SI (Completed) GB (Completed) Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2018-000407-16 Sponsor Protocol Number: PI2018_843_0007 Start Date*: 2018-12-05
    Sponsor Name:CHU Amiens-Picardie
    Full Title: Prospective multicenter randomized double-blind study comparing caspofungin to placebo for the treatment of ICU yeast intra-abdominal infection
    Medical condition: intraabdominal yeast infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004820-41 Sponsor Protocol Number: MK-7625A-035 Start Date*: 2017-08-23
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropen...
    Medical condition: Complicated intra-abdominal infection (cIAI)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10056570 Intra-abdominal infection LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LT (Completed) ES (Completed) HU (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-005779-86 Sponsor Protocol Number: GFT505-208-3 Start Date*: 2008-12-26
    Sponsor Name:GENFIT
    Full Title: A Pilot study to evaluate the Efficacy and Safety of GFT505 (80 mg) orally administered once daily for 28 days in atherogenic dyslipidaemic patients with abdominal obesity. A double blind, placebo-...
    Medical condition: Atherogenic dyslipidaemic patients with abdominal obesity
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058108 Dyslipidaemia LLT
    9.1 10059179 Abdominal obesity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-005686-20 Sponsor Protocol Number: 004 Start Date*: 2012-08-20
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of MK-7655 + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone in Patients ...
    Medical condition: Patients with Complicated Intra-Abdominal Infection
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004862 10056570 Intra-abdominal infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Prematurely Ended) PT (Completed) GR (Completed) LT (Completed) LV (Completed) EE (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-004337-41 Sponsor Protocol Number: GFT505-207-2 Start Date*: 2008-01-11
    Sponsor Name:GENFIT
    Full Title: A Pilot study to evaluate the Efficacy and Safety of GFT505 orally administered once daily (30 mg) for 28 days in atherogenic dyslipidaemic patients with abdominal obesity. A double blind, placebo-...
    Medical condition: Atherogenic dyslipidaemic patients with abdominal obesity
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059179 Abdominal obesity LLT
    9.1 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005467-16 Sponsor Protocol Number: 55995 Start Date*: 2016-06-01
    Sponsor Name:Maastricht University
    Full Title: Peppermint oil for the treatment of Irritable Bowel Syndrome: optimizing therapeutic strategies using targeted delivery
    Medical condition: Irritable Bowel Syndrome
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-011003-23 Sponsor Protocol Number: GFT505-209-4 Start Date*: 2009-05-28
    Sponsor Name:GENFIT
    Full Title: A Pilot study to evaluate the Efficacy and Safety of GFT505 (80mg) orally administered once daily for 35 days in patients presenting with impaired glucose tolerance and abdominal obesity. A double ...
    Medical condition: patients presenting with impaired glucose tolerance and abdominal obesity
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036481 Pre-diabetes LLT
    9.1 10059179 Abdominal obesity LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-004354-28 Sponsor Protocol Number: S-20120017 Start Date*: 2013-07-02
    Sponsor Name:Børneafdelingen Kolding
    Full Title: Maintenance treatment in childhood constipation. A randomized placebo-controlled intervention study
    Medical condition: Childhood functional constipation.
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001298-57 Sponsor Protocol Number: ISO-44-009 Start Date*: 2006-06-04
    Sponsor Name:GUERBET
    Full Title: Comparison of the diagnostic efficacy of Xenetix 350 and Iomeron 400, for visualisation of the aorta and abdominal vascular tree with 64-slices computed tomography
    Medical condition: Patients scheduled for an abdominal MSCT angiography.
    Disease: Version SOC Term Classification Code Term Level
    9.0 10063983 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) BE (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023219-32 Sponsor Protocol Number: GFT505-210-6 Start Date*: Information not available in EudraCT
    Sponsor Name:GENFIT
    Full Title: A Pilot study to evaluate the Efficacy of GFT505 (80mg) orally administered once daily for 8 weeks on insulin sensitivity and hepatic glucose production using a glucose clamp technique and Safety i...
    Medical condition: Patients with insulin resistance and abdominal obesity
    Disease: Version SOC Term Classification Code Term Level
    12.1 10036481 Pre-diabetes LLT
    12.1 10059179 Abdominal obesity LLT
    12.1 10022489 Insulin resistance LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-002368-42 Sponsor Protocol Number: LUM-001 Start Date*: 2017-10-12
    Sponsor Name:Lument AB
    Full Title: An open, randomized, controlled, single centre trial to evaluate CT image quality and diagnostic feasibility of Lumentin® 44, a new egg albumen based oral bowel filling agent, in comparison with di...
    Medical condition: None. Lumentin 44 is a contrast agent and the contrast properties will be investigated in this trial. Patients referred to computerised tomography of the abdomen will be included in the trial. Nei...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004848 10011603 CT scan LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-002120-14 Sponsor Protocol Number: 3074K4-2207-WW Start Date*: 2008-10-29
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceutical Inc.
    Full Title: A Multicenter, Open-Label, Ascending Multiple-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age With Selected Serious Infections
    Medical condition: Complicated intra-abdominal infections (cIAI), complicated skin and skin structure infections (cSSSI), community-acquired pneumonia (CAP).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056570 Intra-abdominal infection LLT
    9.1 10040872 Skin infection LLT
    9.1 10010120 Community acquired pneumonia LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-002726-39 Sponsor Protocol Number: D4910C00009/C3601001 Start Date*: 2016-02-25
    Sponsor Name:Pfizer Inc.
    Full Title: A Phase IIa prospective, open-label, multicenter study to determine the pharmacokinetics (PK) and safety and tolerability of aztreonam-avibactam (ATM-AVI) for the treatment of complicated Intra-Abd...
    Medical condition: Complicated Intra-Abdominal Infections (cIAIs) in hospitalized adults
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-004159-56 Sponsor Protocol Number: MERISUDD Start Date*: 2017-10-12
    Sponsor Name:DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA - UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II
    Full Title: Efficacy and safety of mesalazine, rifaximin, alone or as extemporary combination, in the treatment of symptomatic uncomplicated diverticular disease of colon: multi-centre, randomised, double-blin...
    Medical condition: Treatment of symptomatic uncomplicated diverticular colon disease (SUDD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10013538 Diverticulitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000132-27 Sponsor Protocol Number: CPR-EFC4492-EN Start Date*: 2006-07-27
    Sponsor Name:sanofi-aventis R&D
    Full Title: Satavaptan Cirrhotic Ascites Treatment Study: a double-blind, randomised, parallel-group comparison of treatment with satavaptan at 5 to 10 mg daily versus placebo on top of conventional treatment ...
    Medical condition: Cirrhotic ascites
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003445 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (Completed) BE (Completed) ES (Completed) SE (Completed) HU (Completed) PT (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000381-35 Sponsor Protocol Number: OVG 2011/02 Start Date*: 2011-09-26
    Sponsor Name:University of Oxford
    Full Title: Understanding typhoid disease after vaccination: a single centre, randomised, double-blind, placebo-controlled study to evaluate M01ZH09 in a healthy adult challenge model, using Ty21a vaccine as a...
    Medical condition: Active immunisation for the prevention of typhoid infection in healthy adults.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10045275 Typhoid fever PT
    14.0 10021881 - Infections and infestations 10045272 Typhoid LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2013-004423-36 Sponsor Protocol Number: MK-8616-104 Start Date*: 2015-01-12
    Sponsor Name:MSD Italia s.r.l.
    Full Title: Randomized, parallel group, controlled trial to compare two different “NMB + reversal” strategies in adult obese patients underwent laparoscopic abdominal surgery (Phase 4; Protocol No. MK-8616-104...
    Medical condition: Obese adults to be subjected to abdominal laparoscopic surgery
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002394-22 Sponsor Protocol Number: RFIB3053 Start Date*: 2013-09-26
    Sponsor Name:Salix Pharmaceuticals, Inc.
    Full Title: A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects with Irritable Bowel Syndrome with Diarrhoea (IBS-D)
    Medical condition: Irritable bowel syndrome (IBS) is a heterogeneous gastrointestinal (GI) disorder characterized by frequent and debilitating symptoms (e.g. diarrhoea, bloating, abdominal pain, urgency to defecate, ...
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004856 10060849 Diarrhoea predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002708-28 Sponsor Protocol Number: REDIV/002/17 Start Date*: 2018-02-23
    Sponsor Name:Alfasigma S.p.a
    Full Title: Rifaximin delayed release (400 mg tablet) for the prevention of recurrent acute diverticulitis and diverticular complications. A phase II, multicenter, double-blind, placebo-controlled, randomized ...
    Medical condition: Prevention of recurrent acute diverticulitis and diverticular complications
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10052812 Acute diverticulitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed) HU (Completed) FR (Completed) NL (Completed) GB (GB - no longer in EU/EEA) PT (Completed) IT (Prematurely Ended) RO (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 20:00:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA